摘要
目的探讨亚甲基四氢叶酸还原酶(MTHFR)基因多态性与乳腺癌替吉奥治疗效果的关系。方法选择乳腺癌女性患者138例,所有患者化疗前,提取白细胞DNA,用PCR-RFLP技术检测MTHFR基因型,患者均采用替吉奥治疗,并进行随访,记录其近期及远期生存情况、化疗不良反应发生率,探究MTHFR多态性与治疗效果关系。结果138例患者中携带MTHFR C677T T/T、C/T、C/C的临床有效率分别为87.50%、73.85%、45.45%,Ⅰ~Ⅲ级化疗不良反应发生率分别为82.50%、66.15%、36.36%,T/T基因型临床有效率及化疗不良反应发生率均高于C/C基因型(P<0.05),与C/T基因型无明显差异(P>0.05)。携带MTHFR A1298C基因型患者中A/A、A/C、C/C化疗有效率及分别为74.75%、61.54%、0,Ⅰ~Ⅲ级化疗不良反应发生率分别为68.69%、51.28%、0,A/A基因型患者的临床有效率及化疗不良反应发生率与A/C及C/C患者比较差异无统计学意义(P>0.05)。138例患者中其中携带MTHFR C677T T/T、C/T、C/C基因型患者的3年无进展生存率分别为80.00%、69.23%、30.30%,3年总生存率分别为90.00%、87.69%、60.61%,T/T基因型的3年无进展生存率及3年总生存率均高于C/C基因型(P<0.05),与C/T基因型均无统计学差异(P>0.05);MTHFR A1298C A/A、A/C、C/C基因型3年无进展生存率分别为66.67%、53.85%、0,3年总生存率分别为84.85%、74.36%、0,A/A基因型3年无进展生存率及3年总生存率与A/C、C/C基因型比较无统计学差异(P>0.05)。结论MTHFR基因多态性与乳腺癌替吉奥治疗临床疗效存在着相关性,对预测疗效有一定前景。
Objective To explore the relationship between polymorphisms of methylenetetrahydrofolate reductase(MTHFR)gene and the clinical curative effect of Tegafur Gimeracil Oteracil Potassium Capsule(S-1)on breast cancer.Methods A total of 138 female patients with breast cancer were enrolled.Before chemotherapy,leukocyte DNA was extracted from all patients to detect MTHFR genotypes by PCR-RFLP.All were treated with S-1 and followed up.The short-term and long-term survival,and the incidence of adverse chemotherapy reactions were recorded.The relationship between MTHFR polymorphism and curative effect was explored.Results Among the 138 patients with MTHFR C677T T/T,C/T and C/C,the clinical response rates were 87.50%,73.85%and 45.45%,respectively.The incidence rates of adverse chemotherapy reactions at grades I-III were 82.50%,66.15%and 36.36%,respectively.The clinical response rate and the incidence of adverse chemotherapy reactions in patients with T/T genotype were higher than those with C/C genotype(P<0.05),without significant difference compared with those with C/T genotype(P>0.05).In patients with MTHFR A1298C genotype,the response rates of chemotherapy for A/A,A/C and C/C were 74.75%,61.54%and 0,respectively.The incidence rates of adverse chemotherapy reactions at gradesⅠ~Ⅲwere 68.69%,51.28%and 0,respectively.There were no significant differences in the clinical response rate and the incidence of adverse chemotherapy reactions between patients with A/A genotype and those with A/C and C/C genotype(P>0.05).The 3-year progression-free survival rates and 3-year overall survival rates in patients with MTHFR C677T T/T,C/T and C/C were(80.00%,69.23%,30.30%)and(90.00%,87.69%,60.61%),respectively.The 3-year progression-free survival rate and 3-year overall survival rate in patients with T/T genotype were higher than those with C/C genotype(P<0.05),without significant difference compared with those with C/T genotype(P>0.05).The 3-year progression-free survival rates and 3-year overall survival rates in patients with MTHFR A
作者
丁明明
李芸蕊
郑芝欣
袁小笋
DING Mingming;LI Yunrui;ZHENG Zhixin(Nanyang Central Hospital,Nanyang,473000)
出处
《实用癌症杂志》
2021年第10期1700-1704,共5页
The Practical Journal of Cancer
关键词
亚甲基四氢叶酸还原酶
基因多态性
乳腺癌
替吉奥
临床疗效
Methylenetetrahydrofolate reductase
Gene polymorphism
Breast cancer
Tegafur Gimeracil Oteracil Potassium Capsule
Clinical curative effect
